The European Medicines Agency (EMA) considers that the benefits of the AstraZeneca vaccine continue to outweigh the risks despite several cases of thrombosis after administration of this formulation.
Since the start of vaccination, out of 3.2 million injections performed with AstraZeneca, the results are now 27 cases of thrombosis, including 8 deaths.
Read also: Jean-Michel Blanquer will be vaccinated on Saturday with the AstraZeneca
Five new cases of atypical thrombosis (clots), associated with AstraZeneca's Covid-19 vaccine, were recorded in France between April 9 and April 15, but none caused new deaths, according to health authorities.
While this vaccine has been reserved since March 19 for people aged 55 and over, due to this adverse effect, these 5 new cases of these atypical thromboses have occurred in patients with an average age of 63 years, according to the weekly follow-up report from the French Medicines Agency (ANSM).
The EMA further specifies that the efficacy of this vaccine increases with the age of patients.
